NSCLC patients with EGFR activating mutations have an excellent response to EGFR-TKIs; however, approximately 20–30% of NSCLC patients with EGFR mutations show de novo resistance to EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.